সুইডেন - সুইডিশ - Läkemedelsverket (Medical Products Agency)

pfizer ab - pamidronatdinatrium, vattenfri - koncentrat till infusionsvätska, lösning - 6 mg/ml - mannitol hjälpämne; pamidronatdinatrium, vattenfri 6 mg aktiv substans - pamidronat

সুইডেন - সুইডিশ - Läkemedelsverket (Medical Products Agency)

pfizer ab - pamidronatdinatrium, vattenfri - koncentrat till infusionsvätska, lösning - 9 mg/ml - mannitol hjälpämne; pamidronatdinatrium, vattenfri 9 mg aktiv substans - pamidronat

সুইডেন - সুইডিশ - Läkemedelsverket (Medical Products Agency)

map medical technologies oy - natriumjodid(i-123) - injektionsvätska, lösning - 26 mbq/ml - natriumjodid(i-123) 26 mbq aktiv substans - natriumjodid(i-123)

সুইডেন - সুইডিশ - Läkemedelsverket (Medical Products Agency)

cis bio international - natriumjodid(i-131) - oral lösning - 1110 mbq/ml - natriumjodid(i-131) 1110 mbq aktiv substans - natriumjodid(i-131)

সুইডেন - সুইডিশ - Läkemedelsverket (Medical Products Agency)

amersham health as - natriumjodid(i-131) - injektionsvätska, lösning - 200-4000 mbq/ml - natriumjodid(i-131) 200 - 4000 mbq aktiv substans - natriumjodid(i-131)

সুইডেন - সুইডিশ - Läkemedelsverket (Medical Products Agency)

ge healthcare as - natriumjodid(i-131) - kapsel, hård - 37-3700 kbq - natriumjodid(i-131) 37 - 3700 kbq aktiv substans - natriumjodid(i-131)

সুইডেন - সুইডিশ - Läkemedelsverket (Medical Products Agency)

ge healthcare as - natriumjodid(i-131) - oral vätska - 4 - 7 gbq/ml - natriumjodid(i-131) 4000 - 7000 mbq aktiv substans - natriumjodid(i-131)

ইউরোপীয় ইউনিয়ন - সুইডিশ - EMA (European Medicines Agency)

billev pharma aps - lutetium (177lu) chloride - radionuklid imaging - terapeutiska radioaktiva läkemedel - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.

সুইডেন - সুইডিশ - Läkemedelsverket (Medical Products Agency)

amersham health as - natriumjodid(i-125) - injektionsvätska, lösning - 600-1000 mbq/ml - natriumjodid(i-125) 600 - 1000 mbq aktiv substans - radiofarmaka jod-125 natriumjodid

ইউরোপীয় ইউনিয়ন - সুইডিশ - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.